drugset / Trial / NCT07441824

Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis

NCT07441824

Phase 3 Recruiting 140 enrolled Asian Institute of Gastroenterology, India
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with \>50% pancreatic parenchymal necrosis and at least 5% loss of body weight. The primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.

Timeline

Start
2026-04-10
Primary completion
2027-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Amylase Protein / enzyme biologic 18000 iu
Subject Lipase Protein / enzyme biologic 25000 iu
Subject Protease Protein / enzyme biologic 1000 iu